Immunome IMNM Business Segments — Operating Expenses

Similar metrics at other companies

MCRISingle Reportable — Operating Expenses

$108.96M+3.2%

ALMSSingle Reportable — Operating Expenses

$100.15M-15.8%

IOVASingle Reportable — Operating Expenses

$107.98M-12.1%

PCVXReportable Segment — Operating Expenses

$345.85M+91.3%

MCRISingle Reportable — Operating Costs And Expenses

$17.73M+4.7%

INDVReportable Segment — Operating Expenses

$139M-10.9%

Questions, answered.

What is Immunome's business segments — operating expenses?

Immunome (IMNM) reported business segments — operating expenses of -$59.33M in Q1 2026.

How has Immunome's business segments — operating expenses changed year-over-year?

Immunome's business segments — operating expenses decreased by 24.7% year-over-year, from -$47.56M to -$59.33M.

What is the long-term trend for Immunome's business segments — operating expenses?

Over 2 years (2023 to 2025), Immunome's business segments — operating expenses has grown at a 63.9% compound annual growth rate (CAGR), from $123.55M to $332.04M.

What does business segments — operating expenses mean?

The aggregate of all costs incurred to operate the business segment, including research and development, general and administrative, and other operational charges. This metric provides a comprehensive view of the total cash burn or resource consumption required to maintain the segment's activities. It is a key indicator of the company's overall operational scale and cost management discipline.